NCT04741828

Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian

Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian Adults, Adolescent, Children and Infants

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 188 (actual)
• Sponsor: PT Bio Farma · Industry
• Sex: All
• Age: 6 Months – 40 Years
• Healthy volunteers: Accepted

Summary

Vi-DT Typhoid vaccine is a novel vaccine. This study will be done to know the long-term protection and persistent antibody by measured the antibody titer after 2,3,4 and 5 years after immunization.

Detailed description

This study will be done to know the long-term protection and persistent antibody, by measured the antibody titer after 2,3,4 and 5 years after immunization.

Conditions

• Vaccine

Interventions

Type	Name	Description
DRUG	Vi-DT Typhoid Conjugate Vaccine	Typhoid Conjugate Vaccine

Timeline

• Start date: 2021-05-03
• Primary completion: 2024-10-28
• Completion: 2024-12-30
• First posted: 2021-02-05
• Last updated: 2025-06-03

Locations

2 sites across 1 country: Indonesia